-
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial suggests SVR35 may predict overall survival (OS); new data from the…
-
Scottish football unites to tackle most common cancer in young men
Scottish football is uniting this weekend to tackle the most common cancer affecting young men, as clubs across the country back a national awareness campaign encouraging men to check themselves and catch the disease early. “Tackling Testicular Cancer”, led by Cahonas Scotland in partnership with PFA Scotland, is using the reach of the game to…
-
Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor
Pioneering Physician and Interventional Pulmonology Innovator Joins Noah Medical to Accelerate the Next Era of Robotic-Assisted Lung Cancer Diagnosis and Treatment June 03, 2026 08:00 ET | Source: Noah Medical SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) — Noah Medical, a medical robotics company dedicated to earlier, more accurate lung cancer diagnosis, announced the…
-
Niche Group Advances India's Vision Across Organic Farming and Cancer Treatment
At the same time, he revealed that Niche Agriculture and Pharmaceuticals Limited (NAPL) is working on affordable medicines for diseases such as cancer, epilepsy, and Alzheimer’s. Hundreds of PhD scholars were also interviewed and selected for opportunities during the event. Nestled amidst the beauty of nature, the auditorium of CSKHPKV transformed into far more than…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
